BTG and OMNY Partner to Improve Treatment

For the estimated 7,000 individuals bitten by rattlesnakes, copperheads, and cottonmouths in the US each year, “time is tissue” and timely treatment is critical. Patients that are not quickly and appropriately treated are at risk of skin and tissue damage, limb function disability or loss, neurotoxic effects, dangerous internal bleeding, and systemic injury to the heart, stomach, and other organs. This makes it important to understand and manage antivenom stock levels.

Using the OMNY platform, near real-time data about CroFab® stock levels at participating healthcare institutions will be captured and securely shared with BTG and the Rocky Mountain Poison & Drug Center (RMPDC), and in time will expand to additional healthcare providers and poison control centers.

For more details, please click here: https://www.prnewswire.com/news-releases/btg-and-omny-partner-to-improve-treatment-of-snake-bite-victims-847615017.html

0 Comments

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close